Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.36 USD | +9.26% | +43.03% | -83.97% |
07-12 | Goldman Sachs Adjusts Price Target on Amylyx Pharmaceuticals to $4 From $3, Maintains Neutral Rating | MT |
07-10 | Transcript : Amylyx Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.97% | 147M | |
+7.40% | 101B | |
+8.42% | 42.18B | |
-13.04% | 32.26B | |
+80.80% | 29.79B | |
-10.92% | 16.06B | |
+1.93% | 14.45B | |
-6.77% | 12.01B | |
+177.16% | 10.71B | |
+4.12% | 8.89B |
- Stock Market
- Equities
- AMLX Stock
- News Amylyx Pharmaceuticals, Inc.
- Goldman Sachs Adjusts Price Target on Amylyx Pharmaceuticals to $4 From $3, Maintains Neutral Rating